These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12469940)

  • 21. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.
    Leeds JM; Henry SP; Geary R; Burckin T; Levin AA
    Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):435-41. PubMed ID: 11198927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of coagulation by a phosphorothioate oligonucleotide.
    Henry SP; Novotny W; Leeds J; Auletta C; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):503-10. PubMed ID: 9361909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT; Sitaraman S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of cholesteryl-conjugated phosphorothioate oligodeoxynucleotides to Kupffer cells by lactosylated low-density lipoprotein.
    Bijsterbosch MK; Manoharan M; Dorland R; Waarlo IH; Biessen EA; van Berkel TJ
    Biochem Pharmacol; 2001 Sep; 62(5):627-33. PubMed ID: 11585059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.
    Henry SP; Grillone LR; Orr JL; Bruner RH; Kornbrust DJ
    Toxicology; 1997 Jan; 116(1-3):77-88. PubMed ID: 9020509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.
    Mangsbo SM; Sanchez J; Anger K; Lambris JD; Ekdahl KN; Loskog AS; Nilsson B; Tötterman TH
    J Immunol; 2009 Nov; 183(10):6724-32. PubMed ID: 19864604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM; Leeds JM; Mant TG; Amin D; Kisner DL; Zuckerman JE; Geary RS; Levin AA; Shanahan WR
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.
    Henry SP; Denny KH; Templin MV; Yu RZ; Levin AA
    Birth Defects Res B Dev Reprod Toxicol; 2004 Dec; 71(6):359-67. PubMed ID: 15617021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys.
    Monteith DK; Horner MJ; Gillett NA; Butler M; Geary R; Burckin T; Ushiro-Watanabe T; Levin AA
    Toxicol Pathol; 1999; 27(3):307-17. PubMed ID: 10356707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma.
    Yu RZ; Baker B; Chappell A; Geary RS; Cheung E; Levin AA
    Anal Biochem; 2002 May; 304(1):19-25. PubMed ID: 11969184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
    Levin AA
    Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998
    [No Abstract]   [Full Text] [Related]  

  • 33. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.
    Wallace TL; Bazemore SA; Kornbrust DJ; Cossum PA
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1306-12. PubMed ID: 8819516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
    Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK
    Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
    Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
    J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver.
    Bijsterbosch MK; Manoharan M; Dorland R; Van Veghel R; Biessen EA; Van Berkel TJ
    J Pharmacol Exp Ther; 2002 Aug; 302(2):619-26. PubMed ID: 12130724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides.
    Cohen AS; Bourque AJ; Wang BH; Smisek DL; Belenky A
    Antisense Nucleic Acid Drug Dev; 1997 Feb; 7(1):13-22. PubMed ID: 9055034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.
    Masarjian L; de Peyster A; Levin AA; Monteith DK
    Oligonucleotides; 2004; 14(4):299-310. PubMed ID: 15665597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).
    Watanabe TA; Geary RS; Levin AA
    Oligonucleotides; 2006; 16(2):169-80. PubMed ID: 16764540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.